Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 P72R TP53 Y220C |
Therapy | Cyclophosphamide + Epirubicin |
Indication/Tumor Type | breast cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 P72R TP53 Y220C | breast cancer | no benefit | Cyclophosphamide + Epirubicin | Phase I | Actionable | In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661). | 17388661 |
PubMed Id | Reference Title | Details |
---|---|---|
(17388661) | Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. | Full reference... |